ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Goy Discusses Potential for Combination Therapies in MCL

Andre Goy, MD
Published Online:3:54 PM, Wed April 24, 2019

Andre Goy, MD, chief in the division of lymphoma, chairman and director at John Theurer Cancer Center, discusses a few combinations that are being investigated for the treatment of patients with mantle cell lymphoma (MCL).

Investigators are currently looking at combinations with novel agents such as venetoclax (Venclexta), which Goy says is going to be very important in the field of MCL. In addition, CAR T-cell therapy can also play a role in the treatment of patients with relapsed/refractory disease, he says.

Goy says his institution is part of the integration of these novel therapies that have made such an in the relapsed/refractory setting and the next step is determining how they can be brought to the frontline.

For example, a frontline study is currently ongoing with elderly patients who cannot tolerate a dose-intensive therapy, looking at bendamustine/rituximab (Rituxan) with or without ibrutinib (Imbruvica) or acalabrutinib (Calquence), which may become a new standard of care in the field, he says.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.